Table 3.
Characteristics | Category | N | Multivariate | |||
---|---|---|---|---|---|---|
Odds ratio | 95% CI lower | 95% CI upper | P‐value | |||
Age | <65 | 6299 | 1 | NA | NA | NA |
≥65 | 2607 | 0.822 | 0.483 | 1.399 | 0.4709 | |
Sex | Male | 4990 | 1 | NA | NA | NA |
Female | 3916 | 0.608 | 0.347 | 1.064 | 0.0813 | |
Race | White | 7692 | 1 | NA | NA | NA |
Black | 743 | 0.897 | 0.382 | 2.103 | 0.8017 | |
Others | 471 | 0.706 | 0.217 | 2.293 | 0.5619 | |
Body surface area | 0.1 m2 decrease | 8906 | 1.096 | 0.990 | 1.213 | 0.0784 |
Treatment | M | 1609 | 1 | NA | NA | NA |
C | 2364 | 1.035 | 0.449 | 2.384 | 0.9359 | |
M + C | 1385 | 2.553 | 1.188 | 5.486 | 0.0164 | |
M + M | 766 | 2.175 | 0.873 | 5.420 | 0.0952 | |
C + C | 783 | 1.173 | 0.397 | 3.466 | 0.7728 | |
Others | 1999 | 0.646 | 0.217 | 1.929 | 0.4342 | |
Concurrence of radiation therapy | No | 8705 | 1 | NA | NA | NA |
Yes | 201 | 11.392 | 3.408 | 38.076 | <0.0001 | |
Previous history of thoracic radiation therapy | No | 8830 | 1 | NA | NA | NA |
Yes | 76 | 3.166 | 0.734 | 13.662 | 0.1223 | |
Coexistence of pulmonary disease† | No | 8651 | 1 | NA | NA | NA |
Yes | 255 | 1.527 | 0.513 | 4.544 | 0.4468 | |
Smoking history | No | 8794 | 1 | NA | NA | NA |
Ex‐smoker or current smoker | 112 | 1.605 | 0.349 | 7.393 | 0.5434 | |
Coexistence of lung lesion‡ | No | 6163 | 1 | NA | NA | NA |
Yes | 2743 | 1.342 | 0.749 | 2.406 | 0.3233 | |
PS | 0 | 2973 | 1 | NA | NA | NA |
≥2 | 5933 | 1.872 | 1.044 | 3.356 | 0.0353 | |
Solid or hematological malignancy | Solid tumor | 7540 | 1 | NA | NA | NA |
Hematology | 1366 | 2.894 | 1.593 | 5.258 | 0.0005 | |
LDH | Normal | 4403 | 1 | NA | NA | NA |
Elevated | 4503 | 1.146 | 0.704 | 1.864 | 0.5837 |
†Coexistence of pulmonary disease was defined as patient with lung complication or past‐history such as chronic pulmonary lung disease, bronchial asthma, pulmonary embolism, sarcoidosis, pneumothorax, asbestosis and infection. ‡Coexistence of lung lesion was defined as patient with primary lung tumor and/or lung metastases. C, cytotoxic agent; CI, confidence interval; DILS, drug‐induced interstitial lung disease; LDH, lactate dehydrogenase; M, molecular targeted drug; PS, performance status; NA, not applicable.